10-Q · latest 10
What Johnson & Johnson's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 10 signals
JNJ is executing three major restructuring programs to streamline operations, exit non-strategic markets and product lines, and optimize its manufacturing footprint.
$2.4B
Total estimated costs for three major restructuring programs across Innovative Medicine ($700M), Surgery ($650M), and Orthopaedics ($1000M) segments, using...
generic and biosimilar manufacturers
The company is undergoing a major digital transformation to integrate and simplify core business processes and systems across the enterprise.
J&J initiates $750M supply chain restructuring, adding to $1.7B in ongoing programs
The company is overhauling its Innovative Medicine supply chain, MedTech Surgery franchise, and Orthopaedics franchise, with total costs exceeding $2.4B.
$750M
Estimated cost for new Innovative Medicine supply chain restructuring program
J&J faces over $4.6B in remaining liabilities for talc and opioid settlements
The company has remaining balances of approximately $3.7B for talc matters and $0.9B for opioid settlements, representing a significant ongoing cash drain and management distraction.
$4.6B
Remaining balance for talc ($3.7B) and opioid ($0.9B) settlements
J&J initiates $650M-$750M supply chain restructuring, exiting manufacturing locations.
A new restructuring program in the Innovative Medicine segment aims to optimize operations by exiting sites and suppliers by 2029, with $200M in costs already recorded in Q2 2026.
$750M
Upper estimate for supply chain restructuring program costs through 2029
J&J invested $2.4 billion in property, plant, and equipment in the first six months of 2026
The significant capital expenditure demonstrates active investment in manufacturing, R&D facilities, and other physical infrastructure.
$2.4B
Additions to property, plant and equipment in the first six months of 2026
MedTech segment profit margin fell from 15.9% to 13.8% YoY due to tariffs and restructuring costs
The MedTech division is experiencing significant profitability challenges, with margins compressing by 210 basis points.
-2.1%
Year-over-year decrease in MedTech segment income before tax as a percent of sales
J&J focuses on post-acquisition integration of Intra-Cellular (CAPLYTA).
Johnson & Johnson is in the integration phase following its acquisition of Intra-Cellular, focusing on realizing synergies and managing costs.
- SEC EDGAR
10-Q
Filed · 12 signals
J&J launches multi-year initiative to standardize HR, IT, supply chain, and finance systems.
The company is implementing an enterprise-wide initiative to integrate, simplify, and standardize core business processes and systems across multiple functions.
J&J's MedTech segment undergoing $1B restructuring of its Surgery franchise through 2026.
The company is executing a restructuring of its Surgery franchise with an estimated total cost of $0.9 to $1.0 billion, expected to be completed by the end of fiscal 2026.
$1B
High-end estimate for total Surgery franchise restructuring program cost.
Showing 10 of 22 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Johnson & Johnson earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| In 'full launch mode' for new $5B+ blockbuster bladder cancer drugThe company is executing a major launch for Inlexo, a transformative bladder cancer treatment projected to be a $5 billion+ asset. This signals massive investment in sales, marketing, supply chain, and physician education to support the rollout. | |
| Facing significant headwind from STELARA biosimilar competitionThe loss of exclusivity for STELARA is a major competitive and financial headwind, creating pressure to offset revenue loss. This pressure is the primary driver for J&J's aggressive investment in new blockbuster drugs and high-growth MedTech areas to fuel its 'new era of growth'. | |
| Actively pursuing small, strategic acquisitions after 60+ recent dealsThe CFO highlighted a strategy of executing numerous smaller, high-value acquisitions (over 60 in the last two years) rather than large, speculative ones. This indicates they are constantly evaluating and integrating new technologies and companies, creating opportunities for M&A advisory, IT integration, and other related services. | |
| Sustaining massive R&D investment at $3.7 billion in Q3The company continues to invest heavily in innovation, spending $3.7 billion on R&D in a single quarter, representing 15% of sales. This massive, ongoing budget creates significant opportunities for suppliers of research technologies, lab equipment, data analytics, and clinical trial services. | |
| Gaining significant market share across multiple key drug franchisesThe company is successfully growing market share for key products like DARZALEX (multiple myeloma) and TREMFYA (IBD), which grew 40%. This success validates their commercial strategy and indicates they will continue to fund the sales and marketing teams and technologies that are driving these gains. | |
| Navigating high-stakes talc litigation and legal challengesThe company is actively managing ongoing talc litigation, a significant legal and financial issue. The CFO highlighted the upcoming Daubert motions as a key judicial process, indicating this remains a top-level concern that can influence spending on legal tech, risk management, and compliance solutions. |
Signal API · MCP
Track Johnson & Johnson with the Signal API
One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Johnson & Johnson 10-Q
When did Johnson & Johnson file its latest 10-Q?
What did Johnson & Johnson disclose in its latest 10-Q?
What did Johnson & Johnson say on its recent earnings calls?
Where can I read Johnson & Johnson's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .